AI Article Synopsis
- Cystic Fibrosis (CF) is complex and demands a team approach for proper management, with the GALAXY study showing that 25% of patients experience constipation, a major gastrointestinal symptom.
- Quality of Life assessments indicate that many patients are dissatisfied with current treatments, emphasizing the need for better strategies.
- The paper focuses on distinguishing between abdominal pain sources such as constipation and Distal Intestinal Obstruction Syndrome (DIOS), detailing their causes, diagnosis, and treatment in CF patients.
Article Abstract
Cystic Fibrosis (CF) is a complex disorder that requires multidisciplinary expertise for effective management. The GALAXY study estimated the prevalence of constipation to be about 25% among People with Cystic Fibrosis (PwCF), identifying it as one of the common gastrointestinal (GI) symptoms within this patient population. Quality of Life (QoL) assessments uncovered high patient dissatisfaction, highlighting the imperative need for enhanced treatment strategies. Similarly, Distal Intestinal Obstruction Syndrome (DIOS) is a unique condition exclusive to PwCF that, if left undiagnosed, can lead to considerable morbidity and mortality. Given the broad spectrum of differential diagnoses for abdominal pain, including constipation and DIOS, it is paramount for healthcare providers to possess a clear understanding of these conditions. This paper aims to delineate various differentials for abdominal pain while elucidating the pathogenesis, diagnostic criteria, and treatment options for managing constipation and DIOS in PwCF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ppul.27104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis.
Pediatr Pulmonol
December 2024
Department of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.
Introduction: Cystic Fibrosis (CF) is a multisystem autosomal recessive disease characterized by thick, sticky mucus which causes lung disease, pancreatic insufficiency, and many other manifestations. Constipation is a common complication in CF and few advances in treatment have been made until recent years. Linaclotide is a treatment approved for chronic idiopathic constipation and irritable bowel syndrome with constipation.
View Article and Find Full Text PDFPersistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine.
Headache
September 2024
Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Objective: To evaluate, in patients with chronic migraine (CM) in real-world conditions, the persistence, effectiveness, and tolerability of erenumab, fremanezumab, and galcanezumab anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) and the persistence and effects of switching.
Background: Anti-CGRP mAbs represent a novel therapeutic approach to the management of CM; however, real-world data on persistence, effectiveness, and tolerability, especially after switching, are scarce.
Methods: This was a retrospective observational cohort study including all patients with CM treated with erenumab, fremanezumab, and/or galcanezumab in a tertiary hospital between January 2019 and December 2022.
Constipation and DIOS: Diagnosis, differential diagnosis, and management.
Pediatr Pulmonol
September 2024
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cardinal Glennon Children's Medical Center, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
Article Synopsis
- Cystic Fibrosis (CF) is complex and demands a team approach for proper management, with the GALAXY study showing that 25% of patients experience constipation, a major gastrointestinal symptom.
- Quality of Life assessments indicate that many patients are dissatisfied with current treatments, emphasizing the need for better strategies.
- The paper focuses on distinguishing between abdominal pain sources such as constipation and Distal Intestinal Obstruction Syndrome (DIOS), detailing their causes, diagnosis, and treatment in CF patients.
Presentation, characteristics and management of obstructive intestinal conditions in cystic fibrosis.
Frontline Gastroenterol
May 2024
Department of Respiratory and Sleep Medicine, Monash Children's Hospital, Melbourne, Victoria, Australia.
Objective: Constipation and distal intestinal obstruction syndrome (DIOS) are common gastrointestinal manifestations of cystic fibrosis (CF). The primary aim was to describe the characteristics of constipation and DIOS hospitalisations in a paediatric and adult CF service over a 12-year period. The secondary aims were to determine the proportion of constipation and DIOS presentations which met the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) CF Working Group definitions and to describe management strategies of both conditions.
View Article and Find Full Text PDFSelective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders.
RSC Med Chem
November 2023
Department of Pediatrics, University of California, San Francisco San Francisco CA USA
A loss of prosecretory Cl channel CFTR activity in the intestine is considered as the key cause of gastrointestinal problems in cystic fibrosis (CF): meconium ileus, distal intestinal obstruction syndrome (DIOS) and constipation. Since CFTR modulators have minimal effects on gastrointestinal symptoms, there is an unmet need for novel treatments for CF-associated gastrointestinal disorders. Meconium ileus and DIOS mainly affect the ileum (distal small intestine).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!